Table 1.
Percentages of Bcl2-associated X protein (Bax) and B-cell lymphoma 2 (Bcl2) protein levels to their corresponding control of either proliferative or senescent cells (HCT116 and MCF7) treated with thymoquinone (TQ).
| HCT116 | MCF7 | |||||||
|---|---|---|---|---|---|---|---|---|
| Proliferative | Senescence | Proliferative | Senescence | |||||
| Control | HCT116 + TQ | Dox5 | HCT116 + Dox5+TQ | Control | MCF7 + TQ | Dox5 | MCF7 + Dox5 + TQ | |
| Bax | 100 | 100.5 ± 3.3 | 100 | 152.4 ± 0.6*** | 100 | 123.4 ± 1.7*** | 100 | 96.3 ± 3.4 |
| Bcl2 | 100 | 101.4 ± 1.3 | 100 | 88.4 ± 0.5*** | 100 | 73.1 ± 0.9*** | 100 | 72.3 ± 0.7*** |
| Bax/Bcl2 ratio | 1 | 0.99 | 1 | 1.72 | 1 | 1.69 | 1 | 1.33 |
Mean ± SD. ***P < .001 versus control or Dox5. Control refers to proliferative-untreated HCT116 or -untreated MCF7. HCT116 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. MCF7 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. Dox5 refers to Sen-HCT116 or Sen-MCF7 with 100 nM Dox for 5 days. HCT116 + Dox5 + TQ refers to Sen-HCT116 with 100 nM Dox for 5 days, then treated with 50 µM TQ for 24 hours. MCF7 + Dox5 + TQ refers to Sen-MCF7 with 100 nM Dox for 5 days then treated with 50 µM TQ for 24 hours.